Zevra Therapeutics
ZVRA
158 hedge funds and large institutions have $342M invested in Zevra Therapeutics in 2025 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 60 increasing their positions, 52 reducing their positions, and 30 closing their positions.
145% more call options, than puts
Call options by funds: $28M | Put options by funds: $11.4M
15% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 52
3.32% less ownership
Funds ownership: 71.08% → 67.76% (-3.3%)
5% less funds holding
Funds holding: 166 → 158 (-8)
10% less capital invested
Capital invested by funds: $379M → $342M (-$37.7M)
23% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 30
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.18M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$6.16M |
| 3 |
Morgan Stanley
New York
|
+$5.69M |
| 4 |
BlackRock
New York
|
+$4.44M |
| 5 |
Jane Street
New York
|
+$3.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$18.4M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$11.7M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$8.63M |
| 4 |
AG
Algert Global
San Francisco,
California
|
-$3.98M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$2.29M |
ZVRA Hedge Fund Activity: Q4 2025 in Review
158 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q4 2025, worth a combined $342M — down 9.9% from $379M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of ZVRA and 23 opened new positions — a net loss of 7 holders — while 52 trimmed existing stakes and 60 added.
The largest buyer was Fidelity Investments, adding an estimated $7.18M. The largest seller was Adage Capital Partners, cutting an estimated $18.4M.
- 158 institutional investors held Zevra Therapeutics (ZVRA) as of Q4 2025, down from 166 in Q3 2025.
- Funds reported $342M of Zevra Therapeutics stock for Q4 2025, down 9.9% quarter-over-quarter.
- 23 funds opened new Zevra Therapeutics positions in Q4 2025 and 30 closed out, a net change of -7 holders.
- The largest Zevra Therapeutics buyer in Q4 2025 was Fidelity Investments, an estimated $7.18M added.
- The largest Zevra Therapeutics seller in Q4 2025 was Adage Capital Partners, an estimated $18.4M sold.
Based on aggregated 13F filings for Q4 2025.